Premium
Synthesis, biological screening, and molecular docking of quinazolinone and quinazolinethione as phosphodiesterase 7 inhibitors
Author(s) -
Elfeky Sherin M.,
Sobahi Tariq R.,
Gineinah Magdy M.,
Ahmed Nesreen S.
Publication year - 2020
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201900211
Subject(s) - chemistry , quinazolinone , anthranilic acid , docking (animal) , active site , stereochemistry , enzyme , thiourea , binding site , molecular model , combinatorial chemistry , biochemistry , organic chemistry , medicine , nursing
N ‐Substituted isatoic anhydrides were used as starting materials for the synthesis of compounds 5–16 through alkali hydrolysis, Schiff base reactions, and oxidation. Compounds 18–23 were obtained by thionation of their oxo isosteres using Lawesson's reagent. Cyclocondesation of anthranilic acid with thiourea afforded compounds 25–27, which were S ‐alkylated to afford compounds 28–30 , which were thionated using Lawesson's reagent to afford 31–33 . The compounds were tested for their in vitro inhibitory activity against the phosphodiesterase 7A (PDE7A) enzyme compared with the selective PDE7 inhibitor BRL50481. All the compounds showed the inhibitory activity on the enzyme at micromolar levels. Compounds 9 and 25 showed the highest inhibitory activity on the enzyme: IC 50 = 0.096 and 0.074 μM, respectively, comparable to BRL50481 (IC 50 = 0.072 μM). The binding mode and binding affinity of the target compounds at the enzyme PDE7A‐binding site were studied through molecular docking. Compounds 9 and 25 showed good recognition at the enzyme‐binding site and were capable of binding in an inhibitory mode similar to the reference compound BRL50481, forming the necessary interactions with the key amino acids. Docking studies and enzyme assay were in agreement.